Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954

Jane Grove, Andrew Lovering, Chris Guise, Paul Race, CJ Wrighton, Scott White, Eva Hyde, Peter Searle

Research output: Contribution to journalArticlepeer-review

61 Citations (Scopus)

Abstract

Escherichia coli nitroreductase (NTR) activates the prodrug CB1954 to a cytotoxic derivative, allowing selective sensitization of NTR-expressing cells or tumors to the prodrug. This is one of several enzyme-prodrug combinations that are under development for cancer gene therapy, and the system has now entered clinical trials. Enhancing the catalytic efficiency of NTR for CB1954 could improve its therapeutic potential. From the crystal structure of an enzyme-ligand complex, we identified nine amino acid residues within the active site that could directly influence prodrug binding and catalysis. Mutant libraries were generated for each of these residues and clones screened for their ability to sensitize E. coli to CB1954. Amino acid substitutions at six positions conferred markedly greater sensitivity to CB1954 than did the WT enzyme; the best mutants, at residue F124, resulted in approximately 5-fold improvement. Using an adenovirus vector, we introduced the F124K NTR mutant into human SK-OV-3 ovarian carcinoma cells and showed it to be approximately 5-fold more potent in sensitizing the cells to CB1954 at the clinically relevant prodrug concentration of 1 micro M than was the WT enzyme. Enhanced mutant NTRs such as F124K should improve the efficacy of the NTR/CB1954 combination in cancer gene therapy.
Original languageEnglish
Article number5532
JournalCancer Research
Volume63
Issue number17
Publication statusPublished - 1 Sep 2003

Fingerprint

Dive into the research topics of 'Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954'. Together they form a unique fingerprint.

Cite this